Limitations of current HIV therapies: opportunities for improvement.
Powderly
William G
WG
Washington University School of Medicine, St. Louis, Missouri, USA.
D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D002318:Cardiovascular Diseases / Q000139:chemically induced; D024921:Drug Resistance, Multiple, Viral / Q000235:genetics; D006678:HIV / Q000187:drug effects / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy* / Q000401:mortality; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D020128:Inhibitory Concentration 50; D011788:Quality of Life; D012307:Risk Factors
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors